Biopharma Industry Impact: argenx Buys Unnatural Products

argenx to Acquire Unnatural Products in Deal Worth Up to $1.15 Billion, Adding Peptide Discovery

AMSTERDAM, Netherlands — November 9, 2026 — argenx (Euronext & Nasdaq: ARGX) announced a definitive agreement to acquire Unnatural Products, Inc. (UNP), a California-based macrocyclic peptide discovery company. The transaction is valued at up to approximately USD 1.15 billion and adds new discovery capabilities to the global Biopharmaceutical Market. argenx said the capabilities could support oral and long-acting medicines for immune-mediated diseases.

argenx already holds a minority stake in UNP and will acquire all remaining shares. The consideration comprises an upfront cash payment of USD 550 million and up to USD 595 million in payments contingent on specified development and regulatory milestones. The boards of both companies have approved the transaction, which is expected to close by the end of the year, subject to customary closing conditions.

UNP’s platform combines parallel experimentation with machine learning to design macrocyclic peptides against difficult-to-drug targets. argenx said these capabilities complement its antibody engineering. After closing, UNP’s team will continue to operate from Santa Cruz, California, which will serve as argenx’s home for peptide discovery, and argenx will contribute its clinical development and commercialization capabilities. The deal builds on more than two years of collaboration.

The global biopharmaceutical market was valued at USD 345.84 billion in 2021, with a projected CAGR of 11.7% from 2022 to 2030, according to Next Move Strategy Consulting.

Key Highlights:

• Total potential consideration is up to approximately USD 1.15 billion, made up of USD 550 million upfront in cash and up to USD 595 million in milestone-contingent payments.

• UNP’s macrocyclic peptide discovery engine will sit alongside argenx’s antibody engineering capabilities.

• argenx cited the potential for oral and long-acting medicines for serious immune-mediated diseases.

• The acquisition is expected to close by the end of 2026, subject to customary closing conditions.

Analyst Insight:

According to analysts at Next Move Strategy Consulting, high R&D investment plays a critical role in biopharmaceutical industry growth. Changing disease patterns and the limited efficacy of some existing drugs sustain demand for product innovation.

NMSC analysts note that immunology is among the key application segments tracked in the industry. Companies are using agreements, joint ventures and product innovation to maintain their positions, while the high cost of biopharmaceutical production remains a restraint.

Industry Outlook:

The agreement adds peptide discovery alongside antibody engineering within argenx’s research organization. Completion remains subject to customary closing conditions. The contingent payments depend on development and regulatory milestones whose achievement is uncertain, as argenx noted in its forward-looking statements.

Source: argenx Newsroom

For More Information: Download FREE Sample on Biopharmaceutical Market Report 

Prepared By: Sanyukta Deb